Verition Fund Management’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
Other funds holding OCUL
SR
Verition Fund Management's OCUL Position: Q3 2026 in Review
Verition Fund Management reduced its Ocular Therapeutix (OCUL) stake by 53% in Q3 2026, selling an estimated $1.56M and leaving 140,000 shares worth $1.07M. The position accounts for 0.01% of the portfolio, ranked #1389.
Verition Fund Management first reported a position in OCUL in Q4 2021 and has held it in 14 quarters since. The position peaked at $4.47M in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.
- Verition Fund Management held 140,000 shares of Ocular Therapeutix worth $1.07M as of Q3 2026.
- Verition Fund Management sold 159,199 Ocular Therapeutix shares in Q3 2026, an estimated $1.56M.
- Ocular Therapeutix made up 0.01% of Verition Fund Management's portfolio in Q3 2026, its #1389 holding.
- Verition Fund Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 14 quarters since.
- Verition Fund Management's Ocular Therapeutix position peaked at $4.47M in Q1 2026.
- 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.
Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.